2014
DOI: 10.1002/ejp.598
|View full text |Cite
|
Sign up to set email alerts
|

Prevalence of pain and relative diagnostic performance of screening tools for neuropathic pain in cancer patients: A cross‐sectional study

Abstract: Background: Neuropathic pain can be overlooked in cancer patients. The advent of screening tools can help in recognizing it. However, little is known about their relative diagnostic performance and factors that affect it. This study evaluated the prevalence of neuropathic pain using several diagnostic strategies in cancer patients undergoing chemotherapy. Methods: Patients attending the Oncology Unit of the investigators' site to continue their chemotherapy schedule were systematically screened for this cross-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
33
0
3

Year Published

2016
2016
2021
2021

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 46 publications
(39 citation statements)
references
References 43 publications
3
33
0
3
Order By: Relevance
“…The developer of the painDETECT endorses use down to age 14 years. A comparison between several neuropathic pain screening tools in adults with cancer found the painDETECT to have a poorer sensitivity (but comparable specificity), when compared with other standard screening tools . However, to our knowledge, the additional neuropathic pain screening tools evaluated have not been used in adolescents.…”
Section: Discussionmentioning
confidence: 88%
See 2 more Smart Citations
“…The developer of the painDETECT endorses use down to age 14 years. A comparison between several neuropathic pain screening tools in adults with cancer found the painDETECT to have a poorer sensitivity (but comparable specificity), when compared with other standard screening tools . However, to our knowledge, the additional neuropathic pain screening tools evaluated have not been used in adolescents.…”
Section: Discussionmentioning
confidence: 88%
“…A study in adult cancer patients referred for palliative radiotherapy for bone metastases found that only 12.5% of patients identified to have neuropathic pain on a screening tool were receiving neuropathic pain medications . A cross‐sectional study of adult cancer patients treated with chemotherapy reported that 56% of those found to have neuropathic pain by focused clinical examination and questioning were not receiving any analgesic medication . Published guidelines on neuropathic pain assessment see value in the use of screening tools to identify patients with possible neuropathic pain .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Their clinical validation record is not comparable. Thus, the DN4 validation study has been tested in a few studies in cancer patients . Garcia del Paredes et al, in a Spanish population, found that only half of the cancer patients with neuropathic pain (diagnosed by clinicians) were actually detected by the DN4 questionnaire, while Perez et al found much better sensitivity and specificity values (87.5% and 88.4%, respectively) in a similar population of the same ethnicity.…”
Section: Discussionmentioning
confidence: 99%
“…The ladder identifies opioids as the principal drug for moderate to severe pain with additional nonopioids and adjuvants introduced as needed (World Health Organization, n.d.). Approved add‐on therapies may include nonsteroidal anti‐inflammatories (NSAIDs), corticosteroids, anticonvulsants, and antidepressants (Perez et al., ). Unfortunately, these drugs are not without side effects and despite following this regimen, a minority of patients, 10%–20%, will still experience significant pain (Benyamin et al., ; WHO, n.d.).…”
Section: Introductionmentioning
confidence: 99%